Clinical Cancer Research with Dr. Vivek Subbiah
Moderated by: Jacqueline Brosnan-Cashman, PhD
Clinical Cancer Research Associate Editor
Watch the recording of the AACR Journal Club session featuring Dr. Vivek Subbiah, discussing his article recently published in Clinical Cancer Research, "Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial." In this paper, Dr. Subbiah and colleagues describe safety and efficacy results of the LIBRETTO-001 Phase I/II trial in patients with RET fusion-positive NSCLCs with intracranial metastases. Brain metastases are a major cause of morbidity and mortality in patients with RET fusion-positive non-small cell lung cancers. Selpercatinib was well tolerated in this patient population, achieving a high intracranial response rate, as well as prolonged intracranial duration of response and intracranial progression-free survival. Based on these data, further clinical assessment of selpercatinib is underway.
Stay tuned for the Q&A session at the end of the recording.
About the Featured Speaker:
Vivek Subbiah, MD is an associate professor in the Investigational Cancer Therapeutics department (a Phase 1 program). He is the Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine division, at The University of Texas MD Anderson Cancer Center.